Thursday, April 25, 2024 3:09:36 AM
April 25 (AFP) -- British pharmaceutical giant AstraZeneca on Thursday said net profit jumped 21 percent in the first three months of the year thanks to strong growth in sales of cancer drugs.
Profit after tax climbed more than one fifth compared with the first quarter last year to $2.18 billion, AstraZeneca said in a results statement.
"AstraZeneca had a very strong start in 2024," chief executive Pascal Soriot said in the statement, which noted a 26-percent increase in revenue from oncology treatments.
Total group sales increased 19 percent to $12.7 billion in the first quarter.
"Our strong pipeline momentum continued and already this year we announced positive trial results for Imfinzi and Tagrisso that were unprecedented in lung cancer," added Soriot.
The first quarter saw the company agree to buy US biopharma firm Fusion for up to $2.4 billion, in its latest expansion into cancer treatments.
Fusion is developing next-generation radiotherapy to treat cancer via precise targeting that minimises damage to healthy cells.
AstraZeneca's latest push into oncology comes after its net profit almost doubled to $6 billion last year as a strong cancer division helped offset a wipeout for sales of its Covid treatments.
Also in the first quarter, the group struck a deal to purchase French biotech specialist Amolyt Pharma for about $1 billion, bolstering its rare diseases division Alexion.
bcp/rfj/yad
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM